Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

Fri, 07th May 2021 09:54

* All adults now free to get AZ shot, on doctor's advice

* Gap between doses can be as little as 4 weeks

* Experts warn on reduced efficacy with shorter gap

* Third wave of pandemic "appears to be broken" - minister
(Recasts to lead on AstraZeneca shift)

By Douglas Busvine and Paul Carrel

BERLIN, May 7 (Reuters) - Health Minister Jens Spahn on
Friday defended another U-turn by Germany on the AstraZeneca
vaccine, saying making it available to all adults who
want it would protect more people against COVID-19 more quickly.

Spahn announced late on Thursday that Germany would make
AstraZeneca available to all adults, subject to consulting a
doctor, and allow people to get a second shot as soon as four
weeks after the first.

The move comes with an eye to the summer holidays and
coincides with the rapid passage of legislation that would free
those fully vaccinated from social distancing measures imposed
to fight the pandemic.

Germany had previously limited the shot from the
Anglo-Swedish drugmaker to people over 60 after post-vaccination
monitoring found rare - and sometimes fatal - cases of blood
clotting, with younger women disproportionately affected.

Before that, its vaccine oversight body had said the shot
could not be given to the elderly because of a lack of data from
clinical trials.

With 70% of older people now inoculated and Germany's
vaccination drive gaining momentum, Spahn said the latest step
on AstraZeneca would offer a vaccination option to people who
would otherwise have to wait.

"We are convinced this offer is attractive for those who
would otherwise not get vaccinated so quickly," Spahn told a
news conference, adding that 1 million AstraZeneca doses would
be sent to doctors' practices next week.

THE SOONER, THE WORSE?

The decision by the federal government follows moves by
several German states to make AstraZeneca more widely available
and comes as the pace of giving shots of mainstay vaccines from
BioNTech/Pfizer and Moderna picks up.

The share of the population that has received a first
vaccine shot has reached 31.5%, with 900,000 getting a dose on
Thursday, putting Germany "in the fast lane" by international
standards, said Spahn.

He said the third wave of the coronavirus pandemic "appears
to be broken" while Germany's top public health official, Lothar
Wieler, said infections were falling across all age groups
thanks to social distancing and the progress on vaccinations.

Confirmed cases rose by 18,485 on Friday, with 284
fatalities, while the seven-day incidence fell to 125.7 cases
per 100,000 people, data from the Robert Koch Institute showed.

However, experts criticised the decision to allow people to
receive the AstraZeneca vaccine at shorter intervals, saying
studies had shown its efficacy to be only around 55% with a
four-week gap and 80% with a 12-week delay to the second shot.

"We have to make it clear that if people shorten the gap
between AstraZeneca doses to enjoy greater freedom of movement
sooner, they are doing so at the cost of their immune
protection," said Carsten Watzl, professor of immunology at the
Dortmund Technical University.

Spahn said this was a decision that people should take with
proper advice, a view seconded by Robert Koch Institute head
Wieler.

"We know that the longer the gap before the second shot the
better the protection," Wieler said. "This is an informed
decision people can take in consultation with their doctors."
(Writing by Douglas Busvine
Editing by Gareth Jones)

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.